The Pattern of Use of Oral NSAIDs with or without Coprescription of Gastroprotective Agent for Arthritic Knee by Korean Practitioners
Purpose: Th e aim of this study was to describe the patterns of use of non-steroidal anti-infl ammatory drugs (NSAIDs) for arthritic knees in clinical practice, particularly focusing on the co-prescription of gastroprotective agents for patients with risk factors for adverse gastrointestinal (GI) ev...
Gespeichert in:
Veröffentlicht in: | Knee Surgery and Related Research, 23(4) 2011, 23(4), , pp.203-207 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Purpose: Th e aim of this study was to describe the patterns of use of non-steroidal anti-infl ammatory drugs (NSAIDs) for arthritic knees in clinical practice, particularly focusing on the co-prescription of gastroprotective agents for patients with risk factors for adverse gastrointestinal (GI) events.
Materials and Methods: Each cross-sectional cohort was a group of outpatients visiting 111 physicians who had prescribed NSAIDs for the patients’arthritic knees for more than three consecutive months. A self-administered questionnaire was completed by each patient and physician.
Results: Nine hundred and forty fi ve patients (48%) of the whole 1,960 patients belonged to the group with a high or very high risk for NSAIDinduced gastropathy determined by northern California Health Maintenance Organization guidelines. Overall, only less than half of the patients were given co-prescription of gastroprotective agents, regardless of the presence or absence of GI symptoms and irrespective of the level of risk for NSAIDinduced gastropathy.
Conclusions: Th e physician prescribing NSAIDs for arthritic knees should monitor any GI symptoms and the patient monitor anylevel for NSAIDinduced gastropathy, and be willing to add gastroprotective agents as necessary in order to prevent serious adverse GI events. KCI Citation Count: 2 |
---|---|
ISSN: | 1225-1623 2234-2451 |